Advertisement

Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer

Published:October 27, 2022DOI:https://doi.org/10.1016/j.jgo.2022.10.010

      Abstract

      Introduction

      Understanding physical function (PF) and quality of life (QoL) treatment effects are important in treatment decision-making for older adults with cancer. However, data are limited for older men with metastatic castration-resistant prostate cancer (mCRPC). We evaluated the effects of treatment on PF and QoL in older men with mCRPC.

      Materials and Methods

      Men aged 65+ with mCRPC were enrolled in this multicenter prospective observational study. PF measures included instrumental activities of daily living, grip strength, chair stands, and gait speed. QoL measures included fatigue, pain, mood, and Functional Assessment of Cancer Therapy (FACT)-General total and sub-scale scores. Outcomes were collected at baseline, three, and six months. Linear mixed effects regression models were used to examine PF and QoL differences over time across various treatment cohorts.

      Results

      We enrolled 198 men starting chemotherapy (n = 71), abiraterone (n = 37), enzalutamide (n = 67), or radium-223 (n = 23). At baseline, men starting chemotherapy had worse measures of PF, QoL, pain, and mood than the other groups. Over time, all PF measures remained stable, pain improved, but functional wellbeing (FWB) and mood worsened significantly for all cohorts. However, change over time in all outcomes was not appreciably different between treatment cohorts. Worst-case sensitivity analyses identified attrition (ranging from 22 to 42% by six months) as a major limitation of our study, particularly for the radium-223 cohort.

      Discussion

      FWB and mood were most prone to deterioration over time, whereas pain improved with treatment. Although patients initiating chemotherapy had worse baseline PF and QoL, chemotherapy was not associated with significantly greater worsening over time compared to other common therapies for mCRPC. These findings may assist in treatment discussions with patients. However, given the modest sample size, attrition, and timeframe of follow-up, the impact of treatment on PF and QoL outcomes in this setting requires further study, particularly for radium-223.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Committee CCSA
        Canadian Cancer Statistics 2019 - Survival Statistics for Prostate Cancer.
        Canadian Cancer Society, 2019
        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • et al.
        Cancer statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33
        • Basch E.
        • Loblaw D.A.
        • Oliver T.K.
        • et al.
        Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
        J Clin Oncol. 2014; 32: 3436-3448
        • Loblaw D.A.
        • Virgo K.S.
        • Nam R.
        • et al.
        Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
        J Clin Oncol. 2007; 25: 1596-1605
        • Fung C.
        • Dale W.
        • Mohile S.G.
        Prostate cancer in the elderly patient.
        J Clin Oncol. 2014; 32: 2523-2530
        • Basch E.M.
        • Somerfield M.R.
        • Beer T.M.
        • et al.
        American Society of Clinical Oncology endorsement of the Cancer Care Ontario practice guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
        J Clin Oncol. 2007; 25: 5313-5318
        • Seruga B.
        • Tannock I.F.
        Chemotherapy-based treatment for castration-resistant prostate cancer.
        J Clin Oncol. 2011; 29: 3686-3694
        • Tannock I.F.
        • de Wit R.
        • Berry W.R.
        • et al.
        Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
        N Engl J Med. 2004; 351: 1502-1512
        • Petrylak D.P.
        • Tangen C.M.
        • Hussain M.H.
        • et al.
        Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
        N Engl J Med. 2004; 351: 1513-1520
        • Ryan C.J.
        • Smith M.R.
        • de Bono J.S.
        • et al.
        Abiraterone in metastatic prostate cancer without previous chemotherapy.
        N Engl J Med. 2013; 368: 138-148
        • de Bono J.S.
        • Logothetis C.J.
        • Molina A.
        • et al.
        Abiraterone and increased survival in metastatic prostate cancer.
        N Engl J Med. 2011; 364: 1995-2005
        • Beer T.M.
        • Armstrong A.J.
        • Rathkopf D.E.
        • et al.
        Enzalutamide in metastatic prostate cancer before chemotherapy.
        N Engl J Med. 2014; 371: 424-433
        • Scher H.I.
        • Fizazi K.
        • Saad F.
        • et al.
        Increased survival with enzalutamide in prostate cancer after chemotherapy.
        N Engl J Med. 2012; 367: 1187-1197
        • Parker C.
        • Nilsson S.
        • Heinrich D.
        • et al.
        Alpha emitter radium-223 and survival in metastatic prostate cancer.
        N Engl J Med. 2013; 369: 213-223
        • Townsley C.
        • Pond G.R.
        • Peloza B.
        • et al.
        Analysis of treatment practices for elderly cancer patients in Ontario.
        Can J Clin Oncol. 2005; 23: 3802-3810
        • Hutchins L.F.
        • Unger J.M.
        • Crowley J.J.
        • et al.
        Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
        N Engl J Med. 1999; 341: 2061-2067
        • Yee K.W.
        • Pater J.L.
        • Pho L.
        • et al.
        Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?.
        J Clin Oncol. 2003; 21: 1618-1623
        • Carter N.
        • Bryant-Lukosius D.
        • DiCenso A.
        • et al.
        The supportive care needs of family members of men with advanced prostate cancer.
        Can Oncol Nurs J = Revue canadienne de nursing oncologique. 2010; 20: 166-176
        • Khafagy R.
        • Shackely D.
        • Samuel J.
        • et al.
        Complications arising in the final year of life in men dying from advanced prostate cancer.
        J Palliat Med. 2007; 10: 705-711
        • Lindqvist O.
        • Rasmussen B.H.
        • Widmark A.
        Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases.
        Eur J Oncol Nurs. 2008; 12: 283-290
        • Penson D.F.
        • Litwin M.
        The physical burden of prostate cancer.
        Urol Clin N Am. 2003; 30: 305-313
        • Yellen S.B.
        • Cella D.F.
        • Leslie W.T.
        Age and clinical decision making in oncology patients.
        J Natl Cancer Inst. 1994; 86: 1766-1770
        • Extermann M.
        • Albrand G.
        • Chen H.
        • et al.
        Are older French patients as willing as older American patients to undertake chemotherapy?.
        J Clin Oncol. 2003; 21: 3214-3219
        • Newcomb P.A.
        • Carbone P.P.
        Cancer treatment and age: patient perspectives.
        J Natl Cancer Inst. 1993; 85: 1580-1584
        • Dorff T.B.
        • Crawford E.D.
        Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer.
        Ann Oncol. 2013; 24: 31-38
        • Network NCC
        NCCN guidelines for treatment of Cancer by site: Prostate Cancer.
        2011
        • Pienta K.J.
        • Smith D.C.
        Advances in prostate cancer chemotherapy: a new era begins.
        CA Cancer J Clin. 2005; 55 (300–18; quiz 323–5)
        • Balducci L.
        Aging, frailty, and chemotherapy.
        Cancer Control. 2007; 14: 7-12
        • Manokumar T.
        • Aziz S.
        • Breunis H.
        • et al.
        A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.
        J Geriatr Oncol. 2016; 7: 81-89
        • Wedding U.
        • Honecker F.
        • Bokemeyer C.
        • et al.
        Tolerance to chemotherapy in elderly patients with Cancer.
        Cancer Control. 2007; 14: 44-56
        • Alibhai S.M.H.
        • Krahn M.D.
        • Cohen M.M.
        • et al.
        Is there age bias in the treatment of localized prostate carcinoma?.
        Cancer. 2004; 100: 72-81
        • Bennett C.L.
        • Greenfield S.
        • Aronow H.
        • et al.
        Patterns of care related to age of men with prostate cancer.
        Cancer. 1991; 67: 2633-2641
        • Unger J.M.
        • Hershman D.L.
        • Martin D.
        • et al.
        The diffusion of docetaxel in patients with metastatic prostate cancer.
        J Natl Cancer Inst. 2015; 107
        • Alibhai S.M.H.
        • Breunis H.
        • Feng G.
        • et al.
        Association of Chemotherapy, enzalutamide, Abiraterone, and radium 223 with cognitive function in older men with metastatic castration-resistant prostate Cancer.
        JAMA Netw Open. 2021; 4: e2114694
        • Alibhai S.M.H.
        • Breunis H.
        • Hansen A.R.
        • et al.
        Examining the ability of the Cancer and aging research group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer.
        Cancer. 2021; 127: 2587-2594
        • Saliba D.
        • Elliott M.
        • Rubenstein L.Z.
        • et al.
        The vulnerable elders survey: a tool for identifying vulnerable older people in the community.
        J Am Geriatr Soc. 2001; 49: 1691-1699
        • Bellera C.A.
        • Rainfray M.
        • Mathoulin-Pelissier S.
        • et al.
        Screening older cancer patients: first evaluation of the G-8 geriatric screening tool.
        Ann. Oncol. 2012; 23: 2166-2172
        • Abdulaziz K.E.
        • Brehaut J.
        • Taljaard M.
        • et al.
        National survey of family physicians to define functional decline in elderly patients with minor trauma.
        BMC Fam Pract. 2016; 17
        • Ling C.H.
        • Taekema D.
        • de Craen A.J.
        • et al.
        Handgrip strength and mortality in the oldest old population: the Leiden 85-plus study.
        Cmaj. 2010; 182: 429-435
        • Xue Q.L.
        • Beamer B.A.
        • Chaves P.H.
        • et al.
        Heterogeneity in rate of decline in grip, hip, and knee strength and the risk of all-cause mortality: the Women’s health and aging study II.
        J Am Geriatr Soc. 2010; 58: 2076-2084
        • Palombaro K.M.
        • Craik R.L.
        • Mangione K.K.
        • et al.
        Determining meaningful changes in gait speed after hip fracture.
        Phys Ther. 2006; 86: 809-816
        • Meretta B.M.
        • Whitney S.L.
        • Marchetti G.F.
        • et al.
        The five times sit to stand test: responsiveness to change and concurrent validity in adults undergoing vestibular rehabilitation.
        J Vestib Res Equilibrium & Orientation. 2006; 16: 233-243
        • Cella D.
        • Eton D.T.
        • Lai J.-S.
        • et al.
        Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of Cancer therapy (FACT) Anemia and fatigue scales.
        J Pain Symptom Manag. 2002; 24: 547-561
        • Bruera E.
        • Kuehn N.
        • Miller M.J.
        • et al.
        The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients.
        J Palliat Care. 1991; 7: 6-9
        • Löwe B.
        • Unützer J.
        • Callahan C.M.
        • et al.
        Monitoring depression treatment outcomes with the patient health questionnaire-9.
        Med Care. 2004; 42: 1194-1201
        • Rothman K.J.
        No adjustments are needed for multiple comparisons.
        Epidemiology. 1990; 1: 43-46
        • Kim V.S.
        • Yang H.
        • Timilshina N.
        • et al.
        The potential role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer.
        University of Toronto, 2022
        • Cella D.
        • Traina S.
        • Li T.
        • et al.
        Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302.
        Ann Oncol. 2018; 29: 392-397
        • Roviello G.
        • Gallicchio R.
        • Bozza G.
        • et al.
        Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223.
        Onco Targets Ther. 2019; 12: 9-13
        • Oudard S.
        • Fizazi K.
        • Sengeløv L.
        • et al.
        Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate Cancer: a randomized phase III trial—FIRSTANA.
        J Clin Oncol. 2017; 35: 3189-3197
        • Basch E.
        • Autio K.
        • Ryan C.J.
        • et al.
        Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
        Lancet Oncol. 2013; 14: 1193-1199
        • Fizazi K.
        • Scher H.I.
        • Miller K.
        • et al.
        Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
        Lancet Oncol. 2014; 15: 1147-1156
        • Jiang X.Y.
        • Atkinson S.
        • Pearson R.
        • et al.
        Optimising radium 223 therapy for metastatic castration-resistant prostate Cancer −5-year real-world outcome: focusing on treatment sequence and quality of life.
        Clin Oncol. 2020; 32: e177-e187
        • Kuppen M.C.P.
        • Westgeest H.M.
        • van den Eertwegh A.J.M.
        • et al.
        Health-related quality of life and pain in a real-world castration-resistant prostate Cancer population: results from the PRO-CAPRI study in the Netherlands.
        Clin Genitourin Cancer. 2020; 18: e233-e253
        • Sawhney R.
        • Sehl M.
        • Naeim A.
        Physiologic aspects of aging: impact on cancer management and decision making, part I.
        Cancer J. 2005; 11: 449-460
        • Sehl M.
        • Sawhney R.
        • Naeim A.
        Physiologic aspects of aging: impact on cancer management and decision making, part II.
        Cancer J. 2005; 11: 461-473
        • Schmid S.
        • Omlin A.
        • Blum D.
        • et al.
        Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.
        Ann Oncol. 2015; 26: 2221-2247
        • Onukwugha E.
        • Mullins C.D.
        • Hsu V.D.
        • Seal B.
        • Hussain A.
        Effect of urologists and medical oncologists on treatment of elderly men with Stage IV prostate cancer.
        Urology. 2011; 77: 1088-1095
        • Watts S.
        • Leydon G.
        • Birch B.
        • et al.
        Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates.
        BMJ Open. 2014; 4e003901
        • Jayadevappa R.
        • Malkowicz S.B.
        • Chhatre S.
        • et al.
        The burden of depression in prostate cancer.
        Psycho-Oncology. 2012; 21: 1338-1345
        • Prasad S.M.
        • Eggener S.E.
        • Lipsitz S.R.
        • et al.
        Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer.
        J Clin Oncol. 2014; 32: 2471-2478
        • Bennett G.
        • Badger T.A.
        Depression in men with prostate cancer.
        Oncol Nurs Forum. 2005; 32: 545-556
        • Colloca G.
        • Colloca P.
        The effects of social support on health-related quality of life of patients with metastatic prostate Cancer.
        J Cancer Educ. 2016; 31: 244-252